Add a Calcium Channel Blocker or Thiazide Diuretic to Losartan
In this 63-year-old male with grade 1 diastolic dysfunction, activity intolerance, and uncontrolled hypertension on losartan 100 mg monotherapy, the next step is to add either a calcium channel blocker (CCB) or a thiazide/thiazide-like diuretic (preferably chlorthalidone or indapamide) to achieve blood pressure control and improve diastolic function.
Rationale for Combination Therapy
Your patient is on maximal-dose losartan monotherapy (100 mg is the maximum approved dose 1) but remains hypertensive with symptomatic activity intolerance. Current guidelines emphasize that most hypertensive patients require combination therapy to achieve BP targets of <130/80 mmHg 2, 3.
First-Line Combination Options
The 2024 ESC guidelines specifically recommend for hypertensive patients with heart failure and diastolic dysfunction that all major antihypertensive classes can be used when no specific drug has proven superiority 3. However, the evidence suggests:
Option 1: Add Hydrochlorothiazide (HCTZ)
- Start with losartan 100 mg/HCTZ 12.5-25 mg combination
- This combination has robust evidence in patients with diastolic dysfunction 4, 5
- In a randomized trial of patients with diastolic dysfunction and exertional hypertension, adding HCTZ to losartan reduced exercise systolic BP from 213 to 197 mmHg and increased exercise tolerance from 894 to 951 seconds while improving quality of life 5
- Another study showed that switching to losartan/HCTZ improved diastolic function markers (E/e' ratio) in diabetic patients and reduced urinary albumin 4
Option 2: Add a Calcium Channel Blocker (Amlodipine)
- Start amlodipine 2.5-5 mg daily in addition to losartan
- A 2020 randomized trial showed that adding amlodipine to controlled hypertensive patients with diastolic dysfunction significantly improved E/e' ratio from 13.0 to 12.0 over 6 months 6
- CCBs are particularly effective for BP reduction and have favorable effects on arterial stiffness
Practical Implementation
Step 1: Choose Your Add-On Agent
- If patient has peripheral edema concerns or is elderly: Start with HCTZ 12.5 mg (can increase to 25 mg)
- If patient has no edema concerns or prefers once-daily simplicity: Consider amlodipine 5 mg
- Both approaches have similar efficacy for BP reduction and diastolic function improvement 6
Step 2: Monitoring
- Recheck BP in 2-4 weeks
- Monitor serum potassium and creatinine (losartan + diuretic can affect electrolytes 1)
- Reassess symptoms of activity intolerance
- If BP remains >130/80 mmHg after 4-6 weeks at adequate doses, consider adding the third agent (making it a triple therapy regimen)
Important Caveats
Avoid Common Pitfalls
- Do not add aliskiren if patient has diabetes (contraindicated with ARBs 1)
- Monitor for hyperkalemia when using losartan, especially if adding potassium-sparing agents later
- Watch for orthostatic hypotension in this 63-year-old patient when intensifying therapy
- Assess medication adherence before escalating—many patients with "uncontrolled" hypertension have adherence issues
When to Consider Resistant Hypertension Workup
If BP remains uncontrolled despite losartan + CCB + thiazide diuretic at optimal doses, this patient would meet criteria for resistant hypertension 2, 3. At that point:
- Screen for secondary causes of hypertension
- Review all medications for BP-interfering effects (NSAIDs, decongestants, etc.)
- Consider adding spironolactone 12.5-25 mg if eGFR ≥45 mL/min/1.73 m² 2, 3
Diastolic Dysfunction Considerations
Grade 1 diastolic dysfunction (impaired relaxation) is the mildest form and often improves with BP control alone 7, 8. The activity intolerance may improve substantially once BP is controlled, as demonstrated in the study where exercise time increased by 57 seconds with losartan/HCTZ 5. There are no specific medications proven to reverse diastolic dysfunction independent of BP control, though SGLT2 inhibitors show promise in emerging data 9.
Target Blood Pressure
Aim for SBP 120-130 mmHg in this patient with diastolic dysfunction, as the 2024 ESC guidelines recommend this range for cardiovascular risk reduction 3. The 2025 AHA/ACC guidelines support a target of <130/80 mmHg 2.